Internal medicine

Pathology

Placebo

Infliximab

Maintenance therapy

Disease

Relative risk

Gastroenterology

Meta-analysis

Randomized controlled trial

Alternative medicine

Chemotherapy

Crohn's disease

Adalimumab

Confidence interval

Clinical trial

Medicine

There are numerous biological therapies and small molecules licensed for luminal Crohn's disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is uncertain. We examined this in a network meta-analysis.

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis